Billionaire investor Carl Icahn, who last year forced board changes at biotechnology company Biogen Idec Inc, may take aim at cross-town rival Genzyme Corp(GENZ), according to a source familiar with the situation.
Icahn bought 1.5 million Genzyme shares in the third quarter, and some observers expect him to increase that stake as he considers a proxy assault on the biotech powerhouse.
On Thursday, however, Genzyme launched a pre-emptive strike against Icahn by announcing it had entered into a collaborative agreement with another activist investor, Ralph Whitworth.
Finish reading the story at reuters.com
And watch a briefing from CNBC:
.
Icahn bought 1.5 million Genzyme shares in the third quarter, and some observers expect him to increase that stake as he considers a proxy assault on the biotech powerhouse.
On Thursday, however, Genzyme launched a pre-emptive strike against Icahn by announcing it had entered into a collaborative agreement with another activist investor, Ralph Whitworth.
Finish reading the story at reuters.com
And watch a briefing from CNBC:
